Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Biocon has reported consolidated financial results for the period ended December 31, 2021
First launches expected in H1 2022
This is the company’s first partnership arrangement in China
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
Subscribe To Our Newsletter & Stay Updated
